Xiyanping aerosol inhalation for pulmonary infection in patients with acute stroke
10.3760/cma.j.issn.1673-4246.2015.02.006
- VernacularTitle:喜炎平雾化吸入治疗急性脑卒中患者肺部感染的临床研究
- Author:
Yuzhuo LI
;
Aizhen LI
;
Jianmei WANG
;
Li ZHANG
;
Qian LI
- Publication Type:Journal Article
- Keywords:
Pneumonia;
Stroke;
Aerosols;
Xiyanping
- From:
International Journal of Traditional Chinese Medicine
2015;(2):118-121
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the therapeutic effectiveness of Xiyanping aerosol inhalation for pulmonary infection in patients with acute stroke. Methods Sixty-three patients with pulmonary infection after acute stroke were enrolled and randomly allocated to either a treatment group or a control group. The control group was treated with anti-infective and apophlegmatisant on the basis of standardized stroke treatment, the treatment group was treated with Xiyanping aerosol inhalation on the basis of the treatment in the control group. All patients were treated for 14 days. The resolution times of symptom and signs, and the changes of inflammatory parameters were compared. Results The total effective rate in the treatment group was significantly higher than that in the control group (93.75%vs. 74.19%;χ2=4.510, P=0.034). The resolution times of symptom and signs, such as cough and excessive phlegm (5.94 ± 1.25 d vs. 6.73 ± 1.48 d;t=2.292, P=0.025),fever (2.72 ± 0.11 d vs. 3.25 ± 0.18 d;t=12.046, P<0.01), pulmonary rale (5.22 ± 1.15 d vs. 7.21 ± 1.21 d;t=6.693, P<0.01), and dyspnea (1.17 ± 0.49 d vs. 2.82 ± 0.61 d;t=11.855, P<0.01) in the treatment group were significantly shorter than those in the control group. White blood cell count (2.55 ± 1.02 ×109/L vs. 3.91 ± 1.25 ×109/L;t=4.738, P<0.01), granulocyte proportion (4.92% ± 1.32% vs. 6.25% ± 1.16%; t=4.738, P<0.01) and lymphocyte proportion (58.62%± 6.15%vs. 65.94%± 6.17%;t=4.716, P<0.01) in the treatment group were significantly lower than those in the control group. Conclusions Xiyanping aerosol inhalation can shorten the resolution times of symptom and signs, and improve the therapeutic effectiveness in patients with pulmonary infection after acute stroke.
